Santhanam Anantha Vijay R, Viswanathan Shivkumar, Dikshit Madhu
Department of Anesthesiology, and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Eur J Pharmacol. 2007 Oct 31;572(2-3):189-96. doi: 10.1016/j.ejphar.2007.06.031. Epub 2007 Jun 29.
The ability of agmatine, formed from L-arginine by the enzyme arginine decarboxylase (ADC), to modulate vasomotor function in rat aorta was investigated in the present study. Agmatine-mediated modulation of vasomotor tone was studied in organ chambers, protein expression quantified by Western blot analysis and cyclic guanosine 5'-monophosphate (cGMP) levels measured by radioimmunoassay. Agmatine (10(-10) to 10(-3) M) produced concentration-dependent relaxations (82+/-5%) in phenylephrine-contracted endothelium intact rat aorta. Relaxations to agmatine were diminished on denudation of endothelium and nitric oxide synthase (NOS) inhibition by L-Nomega-nitro arginine or soluble guanylate cyclase inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (P<0.001) abolished agmatine-mediated relaxations, while relaxations were insensitive to inducible NOS inhibition by 1400W. Agmatine-treated aorta demonstrated increased protein expression of phosphorylated S473-Akt and phosphorylated S1177-endothelial nitric oxide synthase (eNOS), and elevated the levels of cyclic GMP (P<0.01). Agmatine-mediated potentiation of relaxations and elevation of cGMP levels was sensitive to phosphatidylinositol 3'-kinase inhibitor, wortmannin. Relaxations to agmatine were also affected by pre-treatment with tetraethylammonium (P<0.01) or apamin (P<0.05), and were not affected by charybdotoxin. Relaxations to agmatine were partially affected by pre-treatment of aortic rings with barium chloride (P<0.05), and glybenclamide (P<0.05). Results obtained suggest that agmatine activates protein kinase B/Akt to phosphorylate eNOS and elevate cyclic GMP levels to produce vasodilatation of aorta. Agmatine-mediated relaxations in rat aorta seems to be mediated mainly by endothelial NO-mediated activation of small conductance Ca2+-activated K+ channels, and partly by ATP-sensitive and inward rectifying K+ channels.
本研究调查了由精氨酸脱羧酶(ADC)将L-精氨酸转化而成的胍丁胺对大鼠主动脉血管舒缩功能的调节能力。在器官浴槽中研究了胍丁胺对血管舒缩张力的调节作用,通过蛋白质免疫印迹分析定量蛋白质表达,并通过放射免疫分析法测定环磷酸鸟苷(cGMP)水平。胍丁胺(10⁻¹⁰至10⁻³ M)可使去氧肾上腺素预收缩的、内皮完整的大鼠主动脉产生浓度依赖性舒张(82±5%)。去除内皮后,胍丁胺介导的舒张作用减弱,L-Nω-硝基精氨酸抑制一氧化氮合酶(NOS)或1H-[1,2,4]恶二唑并[4,3-a]喹喔啉-1-酮抑制可溶性鸟苷酸环化酶可消除胍丁胺介导的舒张作用(P<0.001),而胍丁胺介导的舒张作用对1400W抑制诱导型NOS不敏感。用胍丁胺处理的主动脉显示磷酸化S473-Akt和磷酸化S1177-内皮型一氧化氮合酶(eNOS)的蛋白质表达增加,且cGMP水平升高(P<0.01)。胍丁胺介导的舒张增强作用和cGMP水平升高对磷脂酰肌醇3'-激酶抑制剂渥曼青霉素敏感。用四乙铵(P<0.01)或蜂毒明肽(P<0.05)预处理也会影响胍丁胺介导的舒张作用,而用蝎毒素预处理则无影响。用氯化钡(P<0.05)和格列本脲(P<0.05)预处理主动脉环,会部分影响胍丁胺介导的舒张作用。所得结果表明,胍丁胺激活蛋白激酶B/Akt使eNOS磷酸化并提高cGMP水平,从而导致主动脉血管舒张。胍丁胺介导的大鼠主动脉舒张似乎主要由内皮源性一氧化氮介导的小电导Ca²⁺激活的K⁺通道激活介导,部分由ATP敏感性和内向整流K⁺通道介导。